RECOVERY Collaborative Group 2023, ' Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. ', Lancet (London, England), vol. 401, no. 10387, pp. 1499-1507 . https://doi.org/10.1016/S0140-6736(23)00510-X
Mumford, A D & Gibbison, B J J 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 Dimitriadis, G K 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 RECOVERY Collaborative Group & Dark, P 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet . https://doi.org/10.1016/S0140-6736(22)01109-6
Lancet (London, England) LANCET RECOVERY Collaborative Group 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) a randomised controlled, open-label, platform trial ', The Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Mumford, A D 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised controlled, open-label, platform trial ', Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Group, RECOVERY C & Dark, P 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. ', Lancet (London, England), vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7
RECOVERY Collaborative Group & Downey, D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Mumford, A D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Lancet (London, England) Group, RECOVERY C, Felton, T, Dark, P & Mathioudakis, A 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5
RECOVERY Collaborative Group & Downey, D 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5 LANCET Mumford, A, Ramanan, A V & Gibbison, B J J & Welch, H F 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5, https://doi.org/10.1016/S0140-6736(21)00149-5 The Lancet RECOVERY Collaborative Group, Felton, T, Evans, D G, Murray, C, Buch, M & Dark, P 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5
Lancet (London, England) Voysey, M, Clemens, S A C, Madhi, S A, Weckx, L Y, Folegatti, P M, Aley, P K, Angus, B, Baillie, V L, Barnabas, S L, Bhorat, Q E, Bibi, S, Briner, C, Cicconi, P, Collins, A M, Colin-Jones, R, Cutland, C L, Darton, T C, Dheda, K, Duncan, C J A, Emary, K R W, Ewer, K J, Fairlie, L, Faust, S N, Feng, S, Ferreira, D M, Finn, A, Goodman, A L, Green, C M, Green, C A, Heath, P T, Hill, C, Hill, H, Hirsch, I, Hodgson, S H C, Izu, A, Jackson, S, Jenkin, D, Joe, C C D, Kerridge, S, Koen, A, Kwatra, G, Lazarus, R, Lawrie, A M, Lelliott, A, Libri, V, Lillie, P J, Mallory, R, Mendes, A V A, Milan, E P, Minassian, A M, McGregor, A, Morrison, H, Mujadidi, Y F, Nana, A, O'Reilly, P J, Padayachee, S D, Pittella, A, Plested, E, Pollock, K M, Ramasamy, M N, Rhead, S, Schwarzbold, A V, Singh, N, Smith, A, Song, R, Snape, M D, Sprinz, E, Sutherland, R K, Tarrant, R, Thomson, E C, Török, M E, Toshner, M, Turner, D P J, Vekemans, J, Villafana, T L, Watson, M E E, Williams, C J, Douglas, A D, Hill, A V S, Lambe, T & Gilbert, S C & Pollard, A J 2021, ' Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK ', The Lancet, vol. 397, no. 10269, pp. 99-111 . https://doi.org/10.1016/S0140-6736(20)32661-1 The Lancet Voysey, M, Clemens, S A C, Madhi, S A, Weckx, L Y, Folegatti, P M, Aley, P K, Angus, B, Baillie, V L, Barnabas, S L, Bhorat, Q E, Bibi, S, Briner, C, Cicconi, P, Collins, A M, Colin-Jones, R, Cutland, C L, Darton, T C, Dheda, K, Duncan, C J A, Emary, K R W, Ewer, K J, Fairlie, L, Faust, S N, Feng, S, Ferreira, D M, Finn, A, Goodman, A L, Green, C M, Green, C A, Heath, P T, Hill, C, Hill, H, Hirsch, I, Hodgson, S H C, Izu, A, Jackson, S, Jenkin, D, Joe, C C D, Kerridge, S, Koen, A, Kwatra, G, Lazarus, R, Lawrie, A M, Lelliott, A, Libri, V, Lillie, P J, Mallory, R, Smith, A, Pollard, A J, Hyams, C & Abeysekera, K W M 2021, ' Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK ', Lancet, vol. 397, no. 10269, pp. 99-111 . https://doi.org/10.1016/S0140-6736(20)32661-1, https://doi.org/10.1016/s0140-6736(20)32661-1 Virologica Sinica